Next Article in Journal
The Profile, Health Seeking Behavior, Referral Patterns, and Outcome of Outborn Neonates Admitted to a District and Regional Hospital in the Upper West Region of Ghana: A Cross-Sectional Study
Previous Article in Journal
Prevalence and Selected Sociodemographic of Movement Behaviors in Schoolchildren from Low- and Middle-Income Families in Nanjing, China: A Cross-Sectional Questionnaire Survey
Previous Article in Special Issue
New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
Open AccessReview

Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond

1
Department of Oncology, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 77030, USA
2
Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 77030, USA
*
Author to whom correspondence should be addressed.
Children 2020, 7(2), 14; https://doi.org/10.3390/children7020014
Received: 15 January 2020 / Revised: 3 February 2020 / Accepted: 4 February 2020 / Published: 17 February 2020
Outcomes for pediatric patients with acute myeloid leukemia (AML) remain poor, highlighting the need for improved targeted therapies. Building on the success of CD19-directed immune therapy for acute lymphocytic leukemia (ALL), efforts are ongoing to develop similar strategies for AML. Identifying target antigens for AML is challenging because of the high expression overlap in hematopoietic cells and normal tissues. Despite this, CD123 and CD33 antigen targeted therapies, among others, have emerged as promising candidates. In this review we focus on AML-specific T cell engaging bispecific antibodies and chimeric antigen receptor (CAR) T cells. We review antigens being explored for T cell-based immunotherapy in AML, describe the landscape of clinical trials upcoming for bispecific antibodies and CAR T cells, and highlight strategies to overcome additional challenges facing translation of T cell-based immunotherapy for AML. View Full-Text
Keywords: acute myeloid leukemia; immunotherapy; chimeric antigen receptor; CAR; bispecific antibodies; BiTE; DART acute myeloid leukemia; immunotherapy; chimeric antigen receptor; CAR; bispecific antibodies; BiTE; DART
Show Figures

Figure 1

MDPI and ACS Style

Epperly, R.; Gottschalk, S.; Velasquez, M.P. Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond. Children 2020, 7, 14.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop